.Attributes Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medication conjugate (ADC) tisotumab vedotin resulted in boosted progression-free as well as overall survival, leading to FDA approval and also a new procedure choice for people.